(firstQuint)YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus.

 The primary purpose of this study is to demonstrate superior effect of YJP-14 three doses, 25, 50 and 100 mg t.

i.

d on endothelial dysfunction in diabetes mellitus indicated as mean change difference of flow-mediated dilation (FMD), compared to placebo group after treatment of 12 weeks.

 The secondary purposes of this study are divided into three as follows; - Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.

i.

d on endothelial dysfunction in diabetes mellitus indicated as mean change difference of FMD, compared to placebo group after treatment of 8 weeks.

 - Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.

i.

d on insulin resistance in diabetes mellitus indicated as mean change difference of Homeostasis Model Assessment-Insulin Resistance (HOMA-IR), compared to placebo group after treatment of 4, 8 and 12 weeks.

 - Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.

i.

d on mean change difference of blood pressure in diabetes mellitus, compared to placebo group after treatment of 4, 8 and 12 weeks.

 The exploratory purposes of this study are divided into two as follows; - Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.

i.

d on blood glucose level in diabetes mellitus indicated as mean change difference of HbA1c, compared to placebo group after treatment of 12 weeks.

 - Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.

i.

d on vascular stiffness in diabetes mellitus indicated as mean change difference of blood lipids (LDL, HDL and TG), compared to placebo group after treatment of 12 weeks.

.

 YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus@highlight

The purpose of this study is to evaluate the safety and efficacy of YJP-14 capsules for the treatment of endothelial dysfunction in patients with diabetes mellitus.

